Vipin Garg | BiotechTV

top of page

Altimmune's CEO Vipin Garg discusses the company's work in MASH with the GLP-1 / glucagon dual agonist, pemvidutide

He explains the rationale for combining GLP-1 and glucagon for MASH, and discusses 24-week data that was released earlier this year....

Sep 9

Altimmune CEO Vipin Garg explains the science of weight loss drugs and makes the case for GLP-1/glucagon

Vipin Garg explains the theory of how GLP-1 cause weight loss and gives the rationale for adding glucagon agonism for added effect.

Company News

Jan 10, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Altimmune's CEO Vipin Garg discusses the company's work in MASH with the GLP-1 / glucagon dual agonist, pemvidutide

Altimmune CEO Vipin Garg explains the science of weight loss drugs and makes the case for GLP-1/glucagon

Follow BiotechTV

Sponsors

Sponsor Spotlight